Your browser is no longer supported. Please, upgrade your browser.
Settings
AXSM Axsome Therapeutics, Inc. daily Stock Chart
AXSM [NASD]
Axsome Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.61 Insider Own0.40% Shs Outstand36.08M Perf Week-7.87%
Market Cap3.07B Forward P/E- EPS next Y-1.68 Insider Trans1.53% Shs Float28.56M Perf Month-13.71%
Income-53.10M PEG- EPS next Q-0.47 Inst Own52.10% Short Float17.61% Perf Quarter270.76%
Sales- P/S- EPS this Y9.40% Inst Trans1.02% Short Ratio3.73 Perf Half Y227.06%
Book/sh0.20 P/B426.00 EPS next Y5.10% ROA-134.10% Target Price144.57 Perf Year921.58%
Cash/sh1.21 P/C70.50 EPS next 5Y- ROE-430.10% 52W Range7.63 - 109.94 Perf YTD-17.57%
Dividend- P/FCF- EPS past 5Y-56.60% ROI- 52W High-22.50% Beta3.37
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low1016.64% ATR6.67
Employees41 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)52.33 Volatility4.76% 6.17%
OptionableYes Debt/Eq2.90 EPS Q/Q-76.60% Profit Margin- Rel Volume0.39 Prev Close87.76
ShortableYes LT Debt/Eq2.81 EarningsFeb 06 BMO Payout- Avg Volume1.35M Price85.20
Recom1.40 SMA20-9.53% SMA5028.05% SMA200151.56% Volume529,010 Change-2.92%
Dec-30-19Reiterated H.C. Wainwright Buy $170 → $200
Dec-17-19Reiterated H.C. Wainwright Buy $30 → $170
Dec-16-19Reiterated Guggenheim Buy $65 → $158
Oct-16-19Initiated Guggenheim Buy $48
Sep-18-19Initiated William Blair Outperform
May-28-19Initiated SunTrust Buy
May-23-19Reiterated H.C. Wainwright Buy $23 → $30
Apr-08-19Initiated SVB Leerink Outperform $25
Mar-15-19Reiterated H.C. Wainwright Buy $15 → $18
Oct-03-16Resumed Brean Capital Buy
Dec-15-15Initiated Cantor Fitzgerald Buy
Dec-14-15Initiated Ladenburg Thalmann Buy
Jan-23-20 09:34AM  Axsome (AXSM) Completes Patient Randomization in TRD Study Zacks
Jan-22-20 07:00AM  Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression GlobeNewswire
Jan-17-20 08:45AM  ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why Zacks
Jan-13-20 06:00AM  Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizers Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate GlobeNewswire
Jan-09-20 02:50PM  Top Biotech Stocks for Q1 2020 Investopedia
Jan-08-20 07:18PM  Top Small Cap Stocks for January 2020 Investopedia
Jan-03-20 10:44AM  3 Top Drug Stocks to Own In 2020 InvestorPlace -6.53%
08:56AM  Do Options Traders Know Something About Axsome (AXSM) Stock We Don't? Zacks
Jan-02-20 07:57AM  The Zacks Analyst Blog Highlights: Cirrus Logic, CIRCOR, Axsome and Digital Turbine Zacks
Dec-31-19 09:26AM  Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study Zacks
08:42AM  Top 2019 Wall Street Stories That May Hit Headlines in 2020 Zacks
Dec-30-19 06:15AM  Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response GlobeNewswire
Dec-27-19 02:19PM  Biotech Rally Sends Nasdaq to 9000: ETFs in Focus Zacks
Dec-24-19 12:15PM  Biotech Leading in Q4: Best ETFs & Stocks Zacks
Dec-23-19 04:19PM  Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Dec-22-19 05:05AM  3 Healthcare Stocks With 100% Street Support TipRanks
Dec-20-19 08:12AM  The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering Benzinga +5.63%
Dec-19-19 12:50PM  Bed Bath & Beyond and 3 more stocks showing momentum MarketWatch +6.40%
12:05PM  4 Momentum Stocks To Watch Benzinga
07:05AM  Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock GlobeNewswire
Dec-18-19 04:01PM  Axsome Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +10.62%
Dec-17-19 07:56AM  The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO Benzinga
07:00AM  Axsome Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-16-19 08:43AM  Axsome shares jump on positive findings for depression drug MarketWatch +70.55%
06:00AM  Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder GlobeNewswire
Dec-11-19 11:04PM  Did Hedge Funds Drop The Ball On Axsome Therapeutics, Inc. (AXSM)? Insider Monkey
Dec-06-19 08:00AM  12 Biotech Stocks Primed For A Short Squeeze Benzinga +5.06%
Dec-04-19 10:02AM  Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
08:20AM  Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up Zacks
07:06AM  The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Benzinga
Dec-03-19 08:56AM  Implied Volatility Surging for Axsome (AXSM) Stock Options Zacks +15.12%
06:00AM  Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy GlobeNewswire
Nov-21-19 07:00AM  Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine GlobeNewswire
Nov-20-19 05:28PM  Edited Transcript of AXSM earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents +7.49%
Nov-07-19 07:00AM  Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire -9.67%
Oct-29-19 07:00AM  Axsome Therapeutics to Report Third Quarter 2019 Financial Results on November 7, 2019 GlobeNewswire
Oct-28-19 01:23PM  Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM) Insider Monkey
07:05AM  Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine GlobeNewswire
07:00AM  Axsome Therapeutics Announces Continued Progress in Clinical Development of AXS-07 for the Acute Treatment of Migraine GlobeNewswire
Oct-21-19 07:00AM  Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy GlobeNewswire
Oct-16-19 07:00AM  Axsome Therapeutics Announces Completion of Patient Enrollment in the GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder GlobeNewswire
05:03AM  Riding 2 Big Winners in Small Biotech TheStreet.com
Oct-03-19 08:41AM  Axsome (AXSM) Catches Eye: Stock Jumps 9.3% Zacks
Oct-02-19 07:00AM  Axsome Therapeutics to Provide Update on Continued Progress at the 2019 Cantor Global Healthcare Conference GlobeNewswire +9.28%
Oct-01-19 08:54AM  Do Options Traders Know Something About Axsome (AXSM) Stock We Don't? Zacks -17.44%
05:53AM  CFO & Principal Accounting Officer Nick Pizzie Just Bought Shares In Axsome Therapeutics, Inc. (NASDAQ:AXSM) Simply Wall St.
Sep-18-19 02:08PM  Axsome Shares Flirt With Record High: How Much Upside Is Left? Benzinga
Sep-04-19 01:25PM  How Much Are Axsome Therapeutics, Inc. (NASDAQ:AXSM) Insiders Spending On Buying Shares? Simply Wall St.
Sep-03-19 07:00AM  Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire
Aug-31-19 01:19AM  Edited Transcript of AXSM earnings conference call or presentation 8-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-29-19 08:58AM  Is the Options Market Predicting a Spike in Axsome (AXSM) Stock? Zacks
Aug-20-19 07:00AM  Axsome Therapeutics Appoints David Marek as Chief Commercial Officer GlobeNewswire
Aug-09-19 11:52AM  Axsome Therapeutics, Inc. (AXSM) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 07:00AM  Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Jul-30-19 07:00AM  Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019 GlobeNewswire
Jul-29-19 07:00AM  Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility GlobeNewswire
Jul-16-19 07:46PM  About to Buy Penny Stocks? Look at These 3 Companies First Motley Fool
Jul-12-19 08:50AM  Implied Volatility Surging for Axsome (AXSM) Stock Options Zacks
07:15AM  5 Best Biotech Stocks of 2019 So Far Motley Fool
Jul-07-19 11:07AM  Here's Why Axsome Therapeutics Stock Rocketed 813% in the First Half of 2019 Motley Fool
Jul-02-19 07:29AM  The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug Benzinga
Jul-01-19 07:00AM  Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes GlobeNewswire
Jun-26-19 06:28PM  Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM) Insider Monkey -6.46%
Jun-25-19 04:19PM  Axsome Initiates Phase III Study on Depression Candidate Zacks
Jun-24-19 07:00AM  Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder GlobeNewswire
Jun-20-19 11:11AM  3 Stocks the World's Best Investors Are Buying Right Now Motley Fool
Jun-07-19 07:00AM  Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders Meeting GlobeNewswire
Jun-05-19 10:45AM  Do Institutions Own Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares? Simply Wall St. -8.96%
Jun-04-19 07:24AM  3 Top Small-Cap Stocks to Buy in June Motley Fool
May-21-19 07:00AM  Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting GlobeNewswire
May-20-19 12:48PM  These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month Motley Fool
May-19-19 09:19AM  Here's Why You'll Regret Ignoring This Biotech Stock Rocket Motley Fool
May-10-19 01:48PM  Edited Transcript of AXSM earnings conference call or presentation 9-May-19 12:00pm GMT Thomson Reuters StreetEvents +6.26%
May-09-19 10:59PM  Axsome Therapeutics, Inc. (AXSM) Q1 2019 Earnings Call Transcript Motley Fool
07:25AM  Axsome: 1Q Earnings Snapshot Associated Press
07:00AM  Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
May-08-19 02:30PM  Harry Boxers four stocks to watch include cybersecurity company Carbon Black MarketWatch
12:22PM  4 Stocks Breaking Out On Earnings & Other News Benzinga
09:27AM  Small-Cap Stocks to Watch in May Motley Fool
09:23AM  What's in the Cards for Fuel Tech (FTEK) in Q1 Earnings? Zacks
May-07-19 04:54PM  What's in Store for Axsome (AXSM) This Earnings Season? Zacks
May-06-19 03:01PM  Axsome Shares Rally After FDA OKs Expedited Regulatory Filings For Depression Drug Benzinga +6.69%
07:00AM  Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine GlobeNewswire
06:30AM  Axsome Therapeutics Announces Expedited Development and Pivotal Status for AXS-05 in the Treatment of Major Depressive Disorder based on FDA Breakthrough Therapy Meeting GlobeNewswire
Apr-29-19 07:00AM  Axsome Therapeutics To Report First Quarter 2019 Financial Results On May 9, 2019 GlobeNewswire
Apr-25-19 09:23AM  2 Ultra-High Growth Stocks to Buy Now Motley Fool
Apr-17-19 07:48AM  Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal Zacks
Apr-16-19 11:07AM  Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up Zacks +8.18%
Apr-15-19 06:00AM  Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation GlobeNewswire +6.32%
Apr-08-19 09:19AM  Here's Why Axsome Therapeutics Rocketed 78.8% Higher in March Motley Fool
Apr-07-19 06:00PM  3 Stocks That Have More Than Tripled So Far in 2019 Motley Fool
Apr-03-19 08:50AM  Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options Zacks
Mar-30-19 12:00PM  3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop Motley Fool
Mar-28-19 06:10PM  Axsome's Depression Drug Gets Breakthrough Therapy Status Zacks
09:49AM  3 Small Biotech Stocks Hitting New Highs Investopedia
07:27AM  Jim Cramer Weighs In On General Electric, Nio, Sprint And More Benzinga
Mar-27-19 08:22AM  UPDATE: Axsome Therapeutics shares soar after FDA grants breakthrough designation to depression drug MarketWatch
07:00AM  Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder GlobeNewswire
Mar-25-19 02:15PM  Here's Why Axsome Therapeutics' Stock Gained as Much as 22.9% Today Motley Fool +25.69%
11:51AM  Have Insiders Been Buying Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares This Year? Simply Wall St.
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes. In addition, it is developing AXS-06 that has completed Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastrointestinal ulcers. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JEFFS ROGERDirectorJan 10Option Exercise10.4660,186629,756116,806Jan 14 04:08 PM
Pizzie NickChief Financial OfficerSep 26Buy24.802,18054,06440,440Sep 30 07:16 AM
JEFFS ROGERDirectorJul 03Option Exercise3.0456,620172,17856,620Jul 05 07:00 AM
Coleman MarkDirectorJun 26Buy23.1015,800364,980668,848Jun 27 07:18 AM
Coleman MarkDirectorJun 25Buy23.254009,300653,048Jun 27 07:18 AM
Pizzie NickChief Financial OfficerJun 11Buy20.801,92039,9361,920Jun 12 07:00 AM
Saad Mark EDirectorMay 23Buy22.333,50078,1557,002May 24 07:19 AM
Coleman MarkDirectorMay 13Buy21.444,65099,696652,648May 15 07:21 AM
Coleman MarkDirectorMar 19Buy12.185,10062,1185,100Mar 21 07:05 AM
Pizzie NickChief Financial OfficerMar 19Buy12.696076160Mar 21 07:05 AM
Pizzie NickChief Financial OfficerMar 19Buy12.585,34067,17736,340Mar 21 07:05 AM